IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Study Design: a Phase II, single-arm, multicenter, prospective, interventional study. Target Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor the KRAS G12C mutation. Treatment Regimen: All enrolled subjects will receive IBI351 combined with cetuximab β injection. Treatment will continue until disease progression (as assessed by the investigator per RECIST 1.1 criteria) or the occurrence of intolerable toxicity. Primary Endpoint: Objective Response Rate (ORR) as assessed by the investigator according to Resp

Trial Details

NCT ID
NCT07198841
Phase
PHASE2
Sponsor
Guangdong Association of Clinical Trials
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IBI351 combined with cetuximab β
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Beijing, China|39.9075,116.39723
  • Foshan, China|23.02677,113.13148
  • Nanchang, China|28.68396,115.85306
  • Nanchang, China|28.68396,115.85306

Key Eligibility Criteria

  • Voluntarily participate in the study and sign the informed consent form (ICF).
  • Male or female subjects aged ≥18 years and ≤75 years at the time of signing the ICF.
  • Life expectancy ≥ 3 months.
  • Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC), metastatic, or recurrent (Stage IV) non-small cell lung …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →